131 related articles for article (PubMed ID: 15073676)
1. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin.
Legrand-Abravanel F; Sandres-Sauné K; Barange K; Alric L; Moreau J; Desmorat P; Vinel JP; Izopet J
J Infect Dis; 2004 Apr; 189(8):1397-400. PubMed ID: 15073676
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
[TBL] [Abstract][Full Text] [Related]
4. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Yuen MF; Lai CL
Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
6. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
7. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
9. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
10. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.
Höroldt B; Haydon G; O'Donnell K; Dudley T; Nightingale P; Mutimer D
Liver Int; 2006 Aug; 26(6):650-9. PubMed ID: 16842320
[TBL] [Abstract][Full Text] [Related]
11. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
13. [Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C].
Arambarri M; Fernández Lucas M; Echarri R; Teruel JL; Alarcón C; Merino JL; Ortuño J
Nefrologia; 2004; 24 Suppl 3():39-42. PubMed ID: 15219067
[TBL] [Abstract][Full Text] [Related]
14. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.
Enomoto M; Nishiguchi S; Shiomi S; Tanaka M; Yokogawa T; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Yano Y; Otani S
Am J Gastroenterol; 2002 Feb; 97(2):420-6. PubMed ID: 11866282
[TBL] [Abstract][Full Text] [Related]
16. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.
Colombatto P; Civitano L; Oliveri F; Coco B; Ciccorossi P; Flichman D; Campa M; Bonino F; Brunetto MR
Antivir Ther; 2003 Dec; 8(6):519-30. PubMed ID: 14760885
[TBL] [Abstract][Full Text] [Related]
17. Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients?
Eskander EF; Abd-Rabou AA; Yahya SM; Shaker OG; Mohamed MS
Clin Biochem; 2012 Jan; 45(1-2):3-6. PubMed ID: 21933670
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagata T; Tamaki J; Azuma M; Kishida Y; Yoshida A; Hikiji AY
Hepatogastroenterology; 1995; 42(5):535-41. PubMed ID: 8751211
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with hepatitis C virus on the waiting list.
Everson GT
Liver Transpl; 2003 Nov; 9(11):S90-4. PubMed ID: 14586902
[TBL] [Abstract][Full Text] [Related]
20. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
Neumann AU; Lam NP; Dahari H; Davidian M; Wiley TE; Mika BP; Perelson AS; Layden TJ
J Infect Dis; 2000 Jul; 182(1):28-35. PubMed ID: 10882578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
